Table 3 Anabolic–androgenic steroid cessation and post-cycle therapy

Likelihood of stopping anabolic–androgenic steroids in next 5 years

Respondents, n = 470 (%)

 1 (Very unlikely)

135 (28.7)

 2

138 (29.4)

 3

96 (20.4)

 4

48 (10.2)

 5 (Very likely)

53 (11.3)

Worries about stopping anabolic–androgenic steroids

Respondents, n = 443 (%)

 Nothing

82 (18.5)

 Recovery of testosterone or fertility

232 (52.4)

 Effects on body composition or physical performance

268 (60.5)

 Access to NHS for advice

107 (24.2)

 Quality of NHS advice

110 (24.8)

 Effectiveness or purity of PCT

182 (41.1)

 Other

20 (4.5)

Interest in participating in a research trial about post-cycle therapy

Respondents, n = 469 (%)

 1 (Not at all interested)

156 (33.3)

 2

76 (16.2)

 3

92 (19.6)

 4

42 (9.0)

 5 (Very interested)

103 (22.0)

Where would be best to access National Health Service (NHS) prescribed post-cycle therapy?

Respondents, n = 470 (%)

 Community e.g., harm prevention clinic or local pharmacy

206 (43.8)

 GP surgery

109 (23.2)

 NHS Specialist clinic e.g., endocrinology

47 (10.0)

 Online service

138 (29.4)